Hepatocellular carcinoma is a highly lethal disease, therefore effective and tolerable treatment is urgently needed.
Advances in understanding the molecular genetics of hepatocellular neoplasia have been made, and developing targeted therapeutics in combination with molecular tumor profiling may help accomplish the goal of precision treatment of patients with hepatocellular carcinoma (HCC).
In a recently published article, Dr. Nelson Yee and Dr. Eric Marks provide an updated review of the genetic abnormalities and mechanisms that drive carcinogenesis of HCC, and discuss the targeted therapeutics clinically investigated in patients with this disease.
The article is published in Current Cancer Drug Targets 2016; volume 16, issue 1, pages 53-70.
Eric I. Marks and Nelson S Yee.
Penn State Hershey Cancer Institute, 500 University Drive, Hershey, Pennsylvania, USA
Read more here: http://www.eurekalert.org/pub_releases/2016-03/bsp-ttg030716.php
Bentham Science 